General
Preferred name
PENTOXIFYLLINE
Synonyms
PMID28870136-Compound-49 ()
BL-191 ()
PTX ()
Oxpentifylline ()
3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione ()
Trental 100 ()
Neotren MR ()
Oxypentifylline ()
Trental ()
NSC-637086 ()
Pentoxiphyllin ()
Trental 400 ()
Pentoxifilina ()
C04AD03 ()
Pentoxil ()
NSC-758481 ()
BL 191 ()
Pentoxifylline-d6 ()
P&D ID
PD000975
CAS
6493-05-6
1185878-98-1
Tags
available
prodrug
drug
Approved by
FDA
First approval
1984
Drug indication
Intermittent claudication
Chronic kidney disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pentoxifylline is a methylated xanthine derivative drug which acts as a competitive non-selective phosphodiesterase (PDE) inhibitor . (GtoPdb)
DESCRIPTION Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
PRICE 29
DESCRIPTION Pentoxifylline (PTX) modulates immunologic activity by stimulating cytokine production. Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It also inhibits platelet aggregation and improves blood flow by increasing erythrocyte and leukocyte flexibility.
DESCRIPTION Inhibits synthesis of tumor necrosis factor alpha (TNF-alpha); phosphodiesterase inhibitor (LOPAC library)
DESCRIPTION Pentoxifylline is a methylxanthine derivative used to treat intermittent claudication caused by chronic occlusive arterial disease of the limbs. It exhibits hemorheological, anti-oxidative, and anti-inflammatory properties. It acts as a non-specific cyclic-3',5'-phosphodiesterase inhibitor. (Enamine Bioactive Compounds)
DESCRIPTION PUBCHEM_BIOASSAY: qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response. (Class of assay: confirmatory); PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors. (Class of assay: confirmatory) (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
4
Compound Sets
27
Axon Medchem Screening Library
3179
Cayman Chemical Bioactives
18720
33244
ChEMBL Approved Drugs
CHEMBL628
ChEMBL Drugs
CHEMBL628
Drug Repurposing Hub
DrugBank
DB00806
DrugBank Approved Drugs
DB00806
DrugCentral
2099
DrugCentral Approved Drugs
2099
DrugMAP
DMTUC9E
DMU3DNC
DrugMAP Approved Drugs
DMU3DNC
DrugMatrix
Enamine Bioactive Compounds
EBC-12154
Guide to Pharmacology
7095
Ki Database
Pentoxifylline
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL628
MedChem Express Bioactive Compound Library
HY-B0715
NCATS Inxight Approved Drugs
SD6QCT3TSU
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
pentoxifylline
TargetMol Bioactive Compound Library
2272-1185
The Spectrum Collection
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
278.14
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
0.19
TPSA
78.89
Fraction CSP3
0.54
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
PDE
Member status
member
MOA
Chitinase Inhibitors
Phosphodiesterase Inhibitors
TNF-alpha Production Inhibitors
phosphodiesterase inhibitor
Target
ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF
PDE inhibitor
Autophagy
HIV
Phosphodiesterase (PDE)
Indication
claudication
Therapeutic Class
Vasodilator Agents
Pathway
Anti-infection
Metabolic Enzyme/Protease
Source data